Last 35 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -6.17 | — | 92.23 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 40.89 | 38.51 | 10.37 | 10.16 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 57.52 | 78.14 | 18.79 | 16.28 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 496.41 | 1991.53 | 40.62 | 312.38 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 718.40 | 186.26 | 57.74 | 72.49 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 718.40 | — | 57.25 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Caris Life Sciences, Inc.'s operating margin was 17.9% in Q4 2025, up 2.8 pp QoQ and down 48.0 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -1.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 63.7% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 19.5% | 68.0% | 62.7% | 47.2% | 53.6% | 50.0% | 47.8% | 63.4% | 61.5% | 61.9% | 48.7% | 47.5% |
| — | -63.7% | +36.0% | +31.2% | -25.6% | -12.8% | -19.2% | -2.0% | +33.4% | +27.8% | +28.6% | -1.2% | -3.9% | |
| Operating Margin | 5.6% | 17.9% | 15.1% | 9.9% | -47.9% | 65.9% | 59.3% | 60.4% | 56.1% | 45.0% | 43.6% | 32.0% | 28.1% |
| — | -72.8% | -74.6% | -83.6% | -185.5% | +46.5% | +36.1% | +88.7% | +99.8% | +40.6% | +33.7% | +0.7% | -16.4% | |
| Net Margin | -66.2% | -132.4% | 11.2% | -39.6% | -84.8% | 50.7% | 44.3% | 44.2% | 22.1% | 19.5% | -0.8% | -1.3% | 7.8% |
| — | -361.0% | -74.7% | -189.5% | -483.0% | +159.7% | +5455.8% | +3592.8% | +182.7% | +542.7% | -109.3% | -107.6% | -53.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -93.2% | -73.5% | 5.2% | -15.9% | — | 6.6% | 5.1% | 5.0% | 2.0% | 2.2% | -0.1% | -0.2% | 1.1% |
| — | -1218.4% | +2.1% | -416.8% | — | +195.0% | +5731.4% | +2702.2% | +78.6% | +423.4% | -106.8% | -107.3% | -59.0% | |
| ROA | -73.2% | -36.8% | 2.5% | -11.5% | -5.8% | 1.6% | 1.3% | 1.4% | 0.5% | 0.5% | -0.0% | -0.0% | 0.3% |
| — | -2335.8% | +86.2% | -952.2% | -1249.8% | +209.6% | +6142.2% | +3037.8% | +87.0% | +432.1% | -107.1% | -107.3% | -58.5% | |
| ROIC | — | — | 16.1% | — | -10.8% | 1.8% | 1.5% | 1.5% | 1.0% | 1.0% | 0.9% | 0.9% | 0.8% |
| — | — | +962.7% | — | -1153.7% | +84.5% | +61.9% | +61.0% | +34.4% | +4.4% | -0.3% | -2.7% | -28.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Caris Life Sciences, Inc.'s Debt/EBITDA ratio is 0.0x, down from 11.4x last quarter — comfortably within a safe range. The current ratio has improved 995.0% YoY to 7.85x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.89 | 0.93 | — | 2.82 | 2.41 | 2.52 | 2.49 | 3.16 | 2.88 | 3.05 | 3.03 |
| — | -100.0% | -63.0% | -63.2% | — | -10.7% | -16.3% | -17.5% | -17.9% | +1.8% | -6.8% | +3.1% | -1.7% | |
| Debt / EBITDA | 0.00 | 0.00 | 11.38 | 17.17 | — | 22.75 | 22.70 | 23.56 | 29.19 | 33.37 | 32.14 | 34.34 | 38.26 |
| — | -100.0% | -49.9% | -27.1% | — | -31.8% | -29.4% | -31.4% | -23.7% | -0.3% | -9.6% | +11.3% | +26.0% | |
| Current Ratio | 7.85 | 7.85 | 9.93 | 9.24 | 1.05 | 0.72 | 0.45 | 0.74 | 0.67 | 0.82 | 0.75 | 1.07 | 1.74 |
| — | +995.0% | +2098.8% | +1142.9% | +57.2% | -12.6% | -39.6% | -30.3% | -61.4% | -33.2% | -43.0% | +96.8% | +235.9% | |
| Quick Ratio | 7.85 | 7.85 | 9.36 | 8.79 | 0.83 | 0.72 | 0.45 | 0.74 | 0.67 | 0.82 | 0.75 | 1.07 | 1.74 |
| — | +995.0% | +1971.9% | +1082.4% | +23.6% | -12.6% | -39.6% | -30.3% | -61.4% | -33.2% | -43.0% | +96.8% | +235.9% | |
| Interest Coverage | — | 36.77 | 2.42 | 0.94 | -4.53 | — | 4.57 | 4.36 | 5.18 | 2.14 | 1.88 | 1.65 | 1.47 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCaris Life Sciences, Inc.'s current P/E is -6.2x. The average P/E over the last 1 quarters is 92.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Caris Life Sciences, Inc.'s current operating margin is 5.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Caris Life Sciences, Inc.'s business trajectory between earnings reports.